Description
What is Retatrutide?
Retatrutide (LY3437943) is a 39-amino acid triple receptor co-agonist simultaneously activating GLP-1R, GIPR, and GCGR. GCGR activation adds thermogenesis, fatty acid oxidation, and hepatic glucose production modulation beyond dual GIP+GLP-1 agonism. Phase 2 (NEJM 2023): 24.2% mean weight reduction at 48 weeks at the 12mg dose. The 120mg vial format delivers 1,200mg total per 10-vial kit for extended research protocols. Research use only.
Reviews
There are no reviews yet.